Catechins / ROS Cancer Research Results

Catechins, Catechins: Click to Expand ⟱

Features:

Catechins belong to the category of flavanols, which have two isomeric forms, a positive (+) form and a negative (−) form (epicatechin). The (+)-catechins have antioxidative properties, whereas the (−)-epicatechins act as pro-oxidants inducing oxidative effects.
(−)-epicatechins Examples: EGCG, EGC, GCG GC ECTG, EC (all found in green tea, and maybe dark chocolate)

Catechins — Catechins are flavan-3-ol polyphenols, a chemically heterogeneous class that includes catechin, epicatechin, epigallocatechin, epicatechin gallate, and epigallocatechin gallate, with oncology literature dominated by green-tea catechins, especially EGCG. They are best classified as natural product polyphenols / phytochemicals rather than a single drug entity. Standard abbreviations include GTCs for green tea catechins and EGCG, EGC, ECG, and EC for major individual members. Their principal natural source is Camellia sinensis, although related flavan-3-ols also occur in cocoa and some fruits. In cancer biology, catechins are best understood as pleiotropic redox-active modulators whose apparent mechanism depends strongly on structure, dose, formulation, and tumor context; for broad “catechins” entries, mechanistic confidence is therefore highest for redox stress, glycolytic interference, and apoptosis, and lower for highly specific target claims unless tied to a defined catechin.

Primary mechanisms (ranked):

Redox perturbation with ROS and mitochondrial ROS increase, causing oxidative macromolecular stress and stress-linked growth suppression
Glycolytic suppression, including LDHA inhibition and reduced lactate production in at least some resistant tumor models
Mitochondria-linked apoptotic signaling with caspase activation after sufficient intracellular stress
DNA damage amplification secondary to pro-oxidant chemistry in susceptible cancer settings
Growth-factor and survival signaling attenuation for some gallated catechins, including HGF/MET and downstream AKT/ERK inhibition
Transcriptional and epigenetic modulation, especially with EGCG-rich mixtures, but usually as a secondary rather than defining mechanism for “catechins” as a class

Bioavailability / PK relevance: Oral catechin exposure is limited by instability, intestinal efflux, phase II metabolism, microbial catabolism, and substantial formulation dependence. Peak plasma levels generally occur about 1–3 hours after oral dosing, but systemic concentrations are often only submicromolar to low micromolar, with gallated catechins showing particularly constrained bioavailability. This makes delivery and formulation major translation constraints for internal cancers.

In-vitro vs systemic exposure relevance: Many anticancer in-vitro studies use concentrations above commonly achievable circulating levels after standard oral intake, especially for EGCG-rich extracts and other gallated catechins. Some local luminal effects, tissue accumulation, metabolite activity, or combination effects may still matter biologically, but concentration-driven cell culture findings often overstate likely systemic monotherapy potency in humans.

Clinical evidence status: Strong preclinical literature; small human and phase I-II oncology studies exist mainly for chemoprevention, biomarker modulation, or supportive care, with the most developed signal in prostate cancer prevention settings. There is no approved systemic oncology indication. The only clear regulatory deployment is topical sinecatechins for external genital/perianal warts, which should not be conflated with anticancer approval.

Mechanistic table

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Redox stress and mitochondrial ROS	ROS ↑; mtROS ↑; H2O2 ↑ (context-dependent)	↔ or ROS ↓ at lower / nutritional exposure; injury risk ↑ at high-dose extract exposure	P-R	Stress overload and growth suppression	For broad catechins, the most reproducible cancer-selective mechanism is redox perturbation. This is highly structure-, dose-, and metal-context dependent, and can flip from antioxidant to pro-oxidant behavior.
2	Glycolysis and LDHA	LDHA ↓; lactate production ↓	↔	R-G	Anti-glycolytic pressure and resensitization potential	Direct support exists for catechin suppressing LDHA/lactate output in 5-FU-resistant gastric cancer cells; this is one of the cleaner mechanism-to-phenotype links for the generic catechin entry.
3	Mitochondria and caspase apoptosis	proApCas ↑	↔ or protective at lower exposure	R-G	Intrinsic apoptosis	Usually downstream of redox or metabolic stress rather than a fully independent initiating event.
4	Oxidative DNA damage	DNAdam ↑	↔ or possible damage at high concentration only	R-G	Replication stress and loss of viability	Mechanistically consistent with ROS-generating catechin chemistry; likely relevant mainly in susceptible, copper-rich, or otherwise redox-primed tumor settings.
5	HGF MET survival signaling	MET phosphorylation ↓; AKT/ERK ↓	↔	R-G	Reduced migratory and survival signaling	Best supported for specific gallated catechins such as EGCG and ECG rather than for all catechins equally; included as a class-relevant but not class-defining axis.
6	Transcription and epigenetic modulation	tumor cell viability ↓; survival transcription programs ↓ (context-dependent)	↔	G	Slower proliferation and adaptive restraint	Broad catechin literature often attributes DNMT, NF-κB, AP-1, and related effects, but these data are dominated by EGCG-rich systems and are less secure for the undifferentiated “catechins” category.
7	Clinical Translation Constraint	Oral exposure often below many in-vitro effect levels; extract hepatotoxicity risk; interaction complexity	Liver injury risk is the main normal-tissue concern with concentrated extracts	G	Limits systemic monotherapy translation	Main constraints are low/variable oral bioavailability, dependence on formulation and fed state, uncertain equivalence among catechin mixtures, and clinically relevant safety/interaction questions for concentrated extracts.

TSF: P: 0–30 min
R: 30 min–3 hr
G: >3 hr

Rank	Catechin	Abbreviation	Relative effectiveness	Evidence weight	Main mechanisms	Bioavailability	Cancer selectivity	Key limitations	Notes
1	Epigallocatechin gallate	EGCG	Highest overall	Strongest	ROS modulation, apoptosis, cell-cycle arrest, anti-angiogenic and anti-survival signaling, epigenetic effects	Low to moderate oral bioavailability	Moderate	Poor PK, instability, conjugation, liver risk at high-dose extracts	Best-supported lead catechin overall; usually ranked first across reviews, though not always the most potent in every individual cell-line comparison.
2	Epicatechin gallate	ECG	Very high	Moderate to strong	Antiproliferative activity, apoptosis, membrane and signaling disruption, redox stress	Low oral bioavailability	Moderate	Less studied than EGCG; PK limitations similar to other gallates	Often second overall; in some comparative oral-cancer datasets ECG is among the most cytotoxic and can rival or exceed EGCG.
3	Catechin gallate	CG	Very high to high	Moderate	Antiproliferative activity, apoptosis, redox perturbation	Low oral bioavailability	Unclear to moderate	Small evidence base; relatively sparse in vivo and translational data	Usually ranked close to ECG in direct comparative cell studies; broader evidence base is much thinner than EGCG.
4	Epigallocatechin	EGC	Moderate	Moderate	ROS effects, growth inhibition, apoptosis	Low to moderate oral bioavailability	Unclear to moderate	Generally weaker than gallated catechins	Usually placed below EGCG, ECG, and CG in comparative potency rankings.
5	Gallocatechin gallate	GCG	Moderate	Limited	Likely similar to other gallated catechins: redox modulation, growth inhibition	Likely low oral bioavailability	Unclear	Sparse comparative oncology literature	Could rank higher structurally, but it stays lower here because comparative anticancer evidence is limited.
6	Epicatechin	EC	Low to moderate	Moderate	Milder redox and signaling effects; weaker direct cytotoxicity	Better than EGCG for absorption in some PK settings, but still metabolized extensively	Often favorable tolerability	Usually weak direct anticancer potency	Biologically active, but typically not a lead anticancer catechin when ranked by direct tumor-cell inhibition.
7	Catechin	C	Low	Moderate	Mild antioxidant and signaling effects; limited direct antiproliferative activity	Moderate relative to gallated catechins, but still metabolized	Likely favorable	Weak potency in most comparative cancer-cell studies	Usually grouped among the least cytotoxic tea catechins in direct comparisons.
8	Gallocatechin	GC	Low to unclear	Limited	Presumed redox and signaling effects	Unclear	Unclear	Very sparse comparative anticancer data	Placed last mainly because the evidence base is weak, not because inactivity is established.

ROS, Reactive Oxygen Species: Click to Expand ⟱

Source: HalifaxProj (inhibit)

Type:

Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
• Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
• HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
• SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
• AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
• mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
• HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
• Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy

ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination


Item  ROS↑  NRF2  Condition  Mechanism Class  Remarks  

ROS">Piperlongumine
+++  ↓  [D][T]  ROS-dominant
Selective <span class="wphighlight">ROS</span> stressor, Prevents compensatory upregulation of NRF2, ie GSH↓



ROS">Shikonin
+++ ↓/± [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + glycolysis + GPX4 inhibition



ROS">Vitamin K3 (menadione)
+++ ↓ [D] ROS-dominant
Quinone redox cycler; toxicity limits use



ROS">Copper (ionic / nano)
+++ ↓ [Fe][F] ROS-dominant
Fenton-type redox chemistry



ROS">Sodium Selenite
+++ ↓ [D] ROS-dominant
Pro-oxidant, depletes GSH



ROS">Juglone
+++ ↓ [D] ROS-dominant
Strong quinone <span class="wphighlight">ROS</span> chemistry



ROS">Auranofin
+++ ↓ [D] ROS-dominant
TrxR inhibition → redox collapse



ROS">Photodynamic Therapy (PDT)
+++ 0 [L][O₂] ROS-dominant
Singlet oxygen is core cytotoxic mechanism



ROS">Radiotherapy / Radiation
+++ 0 [O₂] ROS-dominant
DNA damage largely via <span class="wphighlight">ROS</span>



ROS">Doxorubicin
+++ ↓ [D] ROS-dominant
Chemo; redox cycling + mitochondrial <span class="wphighlight">ROS</span>



ROS">Cisplatin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> contributes to DNA/protein damage



ROS">Salinomycin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated CSC toxicity



ROS">Artemisinin / DHA
++ ↓ [Fe][T] ROS-dominant
Iron-activated radical generation



ROS">Sulfasalazine
++ ↓ [C][T] ROS-dominant
Ferroptosis; xCT inhibition → lipid <span class="wphighlight">ROS</span>



ROS">FMD / fasting
++ ↓ [M][C][O₂] ROS-dominant
Metabolic stress → mitochondrial <span class="wphighlight">ROS</span>



ROS">Vitamin C (pharmacologic)
++ ↓ [Fe][D] ROS-dominant
Extracellular H₂O₂ at high dose



ROS">Silver nanoparticles
++ ± [F][D] ROS-dominant
<span class="wphighlight">ROS</span> common; selectivity unreliable



ROS">Gambogic acid
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Parthenolide
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + NF-κB suppression



ROS">Plumbagin
++ ↓ [D] ROS-dominant
Quinone <span class="wphighlight">ROS</span> driver



ROS">Allicin
++ ↓ [D] ROS-dominant
Thiol-reactive oxidative stress



ROS">Ashwagandha (Withaferin A)
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Berberine
++ ↓ [D][M] ROS-dominant
Mitochondrial <span class="wphighlight">ROS</span> induction



ROS">PEITC
++ ↓ [D][C] ROS-dominant
GSH depletion + <span class="wphighlight">ROS</span>



ROS">Methionine restriction
+ ↓ [M][C][T] ROS-secondary
Redox vulnerability increased; <span class="wphighlight">ROS</span> indirect



ROS">DCA
+ ± [M][T] ROS-secondary
<span class="wphighlight">ROS</span> via forced OXPHOS



ROS">Capsaicin
+ ± [D][T] ROS-secondary
Ca²⁺ stress → <span class="wphighlight">ROS</span>



ROS">Galloflavin
+ 0 [D] ROS-secondary
<span class="wphighlight">ROS</span> not primary driver



ROS">Piperine
+ ± [D][F] ROS-secondary
Weak <span class="wphighlight">ROS</span> induction



ROS">Propyl gallate
+ ↓ [D] ROS-secondary
Pro-oxidant at high dose



ROS">Scoulerine
+ ? [D][T] ROS-secondary
Sparse <span class="wphighlight">ROS</span> data



ROS">Thymoquinone
± ± [D][T] Dual redox
Antioxidant ↔ pro-oxidant switch



ROS">Emodin
± ± [D][T] Dual redox
Not cancer-exclusive



ROS">Alpha-lipoic acid (ALA)
± ↑ [D][M] NRF2-dominant
Antioxidant at low dose



ROS">Curcumin
± ↑/↓ [D][F] NRF2-dominant
Hormetic redox behavior



ROS">EGCG
± ↑/↓ [D][O₂] NRF2-dominant
Auto-oxidation artifacts common



ROS">Quercetin
± ↑/↓ [D][Fe] NRF2-dominant
GSH-dependent cycling



ROS">Resveratrol
± ↑ [D][M] NRF2-dominant
<span class="wphighlight">ROS</span> only at high dose



ROS">Sulforaphane
± ↑↑ [D] NRF2-dominant
Strong NRF2 activator



ROS">Lycopene
0 ↑ — Antioxidant
Consistently antioxidant



ROS">Rosmarinic acid
0 ↑ — Antioxidant
Primarily antioxidant



ROS">Citrate
0 0 — Neutral
Metabolic; not a <span class="wphighlight">ROS</span> agent

Scientific Papers found: Click to Expand⟱

603-

Catechins,

Catechins induce oxidative damage to cellular and isolated DNA through the generation of reactive oxygen species

in-vitro,

NA,

HL-60

ROS↑, DNAdam↑, H2O2↑,

939-

Catechins,

5-FU,

Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil

vitro+vivo,

GC,

SNU620

lactateProd↓, ROS↑, tumCV↓, LDHA↓, mt-ROS↑, proApCas↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:

DNA Damage & Repair ⓘ

DNAdam↑, 1,
Total Targets: 8

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:228  Target#:275  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

Catechins / ROS Cancer Research Results

Mechanistic table

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Transcription & Epigenetics ⓘ

DNA Damage & Repair ⓘ

Pathway results for Effect on Normal Cells:

Home Page